24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels (DAPT-Lp(a))

Inclusion Criteria: Male or nonpregnant female between 18-75 years; Subjects with Lp(a) levels > 30mg/dL before percutaneous coronary intervention (PCI); Subjects who are event-free at 1 year after PCI with drug-eluting stent (DES); Subjects (or legal guardian) understand the trial requirements and the treatment procedures and provides written informed; Subjects are willing to comply with all protocol-required follow-up evaluation. Exclusion Criteria: Subjects with Lp(a) < 30mg/dL or Lp(a) level unavailable before PCI; Subjects who experience adverse cardiovascular events (death, myocardial infarction, stent thrombosis, stroke, repeat coronary revascularization, or Bleeding Academic Research Consortium [BARC] type 2, 3 or 5 bleeding) within 1-year after PCI; Subjects who have other diseases requiring dual antiplatelet therapy (DAPT) such as peripheral vascular disease; Subjects who cannot tolerate DAPT therapy or receive anticoagulation therapy at the time of randomization; Planned surgery necessitating discontinuation of antiplatelet therapy (>14 days) within the 12 months after randomization; Systolic blood pressure < 90mmHg for > 30 minutes accompanied by hypoperfusion symptoms or systolic blood pressure ≥ 90mmHg is maintained with mechanical/pharmacologic hemodynamic support; Unstable or severe pulmonary edema/decompensated congestive heart failure; Moderate to severe heart failure (New York Heart Association [NYHA] Functional Classification III or IV) or last known left ventricular ejection fraction (LVEF) < 40%; Severe valvular heart disease, myocarditis or cardiomyopathy; Recurrent symptoms of ischemia; Severe renal dysfunction, defined as creatinine clearance <30 mL/min or estimated glomerular filtration (eGFR) rate less than 30 ml/min/1.73m2, or requirement for peritoneal dialysis or hemodialysis for renal insufficiency; History or clinical evidence of active liver disease or hepatic dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × upper limit of normal (ULN), or total bilirubin > 2 × ULN; Unexplained elevated creatine kinase (CK) concentration >5 × ULN or elevation due to known muscle disease; Severe acute or chronic infectious disease; History of severe rheumatic immune disease or malignant tumor; Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies), or receiving other investigational agent(s); Drug or alcohol abuse, and inability/unwillingness to abstain from drug abuse and excessive alcohol consumption during the study; Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal); Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the subject and investigator's knowledge; Any uncontrolled or serious disease, or any medical or surgical condition (such as known active infection or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction, or a chronic disease or infection [eg, HIV]), that may either interfere with participation in the clinical study and is not currently stable and appropriately managed in the judgment of the investigator, and/or put the subject at significant risk (according to investigator's judgment) if he/she participates in the clinical study; Mental/psychological impairment/neurocognitive disorder, or any other reason to expect patient difficulty in complying with the requirements of the study or understanding the goal and potential risks of participating in the study; Concurrent medical condition with a life expectancy of < 1 year; Subject unable to give informed consent;